SAN CARLOS, Calif., April 21 /PRNewswire-FirstCall/ -- Nuvelo, Inc. , today announced that it will hold a conference call to discuss its first quarter 2006 financial results and accomplishments on Friday, May 5, 2006, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time).
To participate in the conference call, please dial 800-706-7745 for domestic callers and 617-614-3472 for international callers and reference conference passcode, 21460095. A telephone replay of the conference call will be available through Friday, May 19, 2006. To access the replay, please dial 888-286-8010 for domestic callers and 617-801-6888 for international callers and reference conference passcode, 93591578.
In addition, this call is being webcast by Thomson/CCBN and can be accessed at Nuvelo's website at www.nuvelo.com.
The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs focused on alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic- related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that is currently in Phase 2 clinical development for acute coronary syndromes and a thrombin inhibiting aptamer for anticoagulation during medical procedures. Nuvelo is also progressing an emerging oncology pipeline which includes NU206, for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.CONTACT: Nicole Estrin, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472, or nestrin@nuvelo.com
Web site: http://www.nuvelo.com/
